UNSPSC 51433702: Muzolimine

This classification denotes an antihypertensive agent and diuretic with the molecular formula C11H11Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 07Z36289ZX, chemically known as 5-amino-2-(1-(3,4-dichlorophenyl)-ethyl)-2,4-dihydro-3h-pyrazol-3-one but generally known as muzolimine, which bears US NIH Compound Identifier 41386. European Medicines Agency schedules Muzolimine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09097MIG.

UNSPSC 51433702 Muzolimine, a Commodity code, encompasses emergency and critical-care pharmaceutical supplies that state and local governments procure for first-responder and public-health operations. Recent solicitations show state and local buyers acquiring specific medication formulations — epinephrine, labetalol, adenosine, diltiazem, and other generic pharmaceuticals — in quantities ranging from hundreds to thousands of units for fire rescue services, health agencies, and statewide cooperative purchasing consortia. The code attracts municipal purchasing departments, state health agencies, and multistate cooperative purchasing alliances as the primary issuing bodies. The City of Tampa and the Texas Health and Human Services Commission represent the jurisdictional scope — city-level operational procurement paired with state-level policy and supply-chain initiatives.

Activity spans Florida, Texas, and Minnesota, with multistate cooperative mechanisms such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) extending reach across multiple states including Oregon. The City of Tampa issued an Invitation for Bid (IFB) for Advanced Life Support Medications (Solicitation 26P00188) due April 8, 2026, with an estimated contract value of $40,000.00 and a one-year term plus renewal options; Tampa Fire Rescue is the end user. The Texas Health and Human Services Commission released a Request for Information (RFI No. HHS0017013) posted April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state-level movement toward alternative supply-chain models. The Minnesota Department of Administration's MMCAP issued a Request for Proposal (Solicitation S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating government facilities, with contract effectiveness July 1, 2026. Recent opportunities include SLBE set-asides and cooperative purchasing vehicles that expand jurisdictional reach beyond single municipalities.